President Donald Trump has announced TrumpRx.gov, a national portal aimed at making prescription medicines more affordable for Americans. The initiative, reported by Zee Business sources, forms a key part of the administration’s wider healthcare reform agenda and will begin operations in January 2026.
National portal to make medicines affordable
The TrumpRx platform will allow citizens to buy approved prescription drugs directly through a government-backed website, eliminating intermediaries and lowering costs. As reported by Zee Business sources, the portal is built around a new pricing model that promises greater transparency and fairer rates for essential medicines. Officials familiar with the plan said the portal would include a broad range of widely used drugs, including those prescribed for chronic conditions such as diabetes, hypertension and cancer.
Under new supply arrangements with major pharmaceutical companies, some of these medicines could be offered at “near zero” cost.
Add Zee Business as a Preferred Source
AstraZeneca to invest $50 billion in US expansion
In a major development aligned with the initiative, AstraZeneca has announced a $50 billion investment in its US operations over the next five years.
The British-Swedish drugmaker plans to expand its research, manufacturing, and supply capabilities to meet growing demand under the new affordability scheme. According to Zee Business sources, this large-scale investment will strengthen domestic production and reduce the country’s dependence on imported drugs.
AstraZeneca is also expected to work with the US government to develop and distribute low-cost medicines through TrumpRx.gov.
Read More:Â Tariff Wars Far From Over: Trump slaps 100% additional duty on Chinese products entering US
Focus on affordability and healthcare reform
The Trump administration’s initiative marks one of the most ambitious efforts in recent years to reform the nation’s drug pricing system. It seeks to narrow the long-standing gap between medicine prices in the US and those in other developed countries – an issue that has contributed to high healthcare costs for millions of Americans.
The AstraZeneca investment, aligned with this broader vision, is expected to bolster local supply chains and support the production of essential medicines under the TrumpRx framework.
